stockrow
Friday 6 November 2026
Export MYO’s income statement to Excel — free account
Myomo, Inc.
MYO Healthcare Medical Devices
Myomo, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.9 million, up 25.7% from fiscal 2024.
- Revenue
- +21.3%
- EPS
- +18.2%
- Free cash flow
- +80.0%
- Total debt
- +199.5%
Quarter to June 2026, against a year earlier
1.22
0.03
+2.52%
Follow MYO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.90 | 0.93 | 0.70 | 1.03 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.52) | (33.40) | (13.08) | (22.84) | |
P/B ratio |
2.57 | 3.34 | 3.19 | 7.62 | |
Price to Tangible BV |
2.57 | 3.34 | 3.19 | 7.62 | |
EV/Sales |
0.70 | 0.79 | 0.62 | 0.99 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.90) | (2.24) | (1.82) | (6.04) | |
EV/FCF |
(2.09) | (1.82) | (1.49) | (4.72) | |
Quick Ratio |
1.94 | 2.69 | 2.19 | 1.73 | |
Current Ratio |
2.49 | 3.30 | 2.73 | 2.31 | |
Net Debt/EBITDA |
2.80 | 4.23 | 1.94 | 1.01 | |
Debt/Assets |
11.74% | 29.05% | 29.73% | 33.90% | |
Debt/Equity |
0.27 | 0.98 | 1.21 | 2.06 | |
Asset Turnover |
1.65 | 1.01 | 1.06 | 1.17 | |
Operating CF/Net income |
0.50 | 0.30 | 0.73 | 0.48 | |
Capex/Depreciation |
(2.27) | (0.33) | (0.71) | (0.10) | |
Interest Coverage |
— | — | (6.26) | — | |
Research and Development Expense of Revenue |
15.14% | 14.31% | 16.05% | 14.70% | |
Selling, General and Administrative Expense of Revenue |
83.56% | 78.68% | 83.41% | 76.69% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.79% | 4.98% | 5.91% | 8.91% | |
Graham Net Nets |
0.09 | 0.01 | (0.07) | (0.11) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(32.58%) | (40.66%) | (52.94%) | (32.69%) | |
Free Cash Flow Yield |
(36.89%) | (46.85%) | (59.80%) | (20.47%) | |
Revenue per Share |
0.24 | 0.27 | 0.24 | 0.27 | |
Operating CF per Share |
(0.04) | (0.03) | (0.05) | (0.05) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.04) | (0.06) | (0.05) | |
Cash per Share |
0.30 | 0.44 | 0.37 | 0.32 | |
Shareholders Equity per Share |
0.35 | 0.27 | 0.21 | 0.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.35 | 0.27 | 0.21 | 0.14 | |
Free Cash Flow |
(2.88) | (1.49) | (2.69) | (2.02) | |
Working Capital |
13.75 | 19.21 | 16.27 | 13.92 | |
Capital Expenditures |
(1.05) | (0.35) | (0.49) | (0.08) | |
Net Current Asset Value |
3.50 | 0.32 | (2.09) | (4.99) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.10 | 0.03 | 0.05 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.51 | 3.96 | 4.74 | 6.00 | |
Average Payables |
6.56 | 7.42 | 8.73 | 7.91 | |
Average Inventory |
3.51 | 3.14 | 3.46 | 3.65 | |
Average Assets |
25.20 | 40.44 | 38.81 | 37.01 | |
Average Common Equity |
11.96 | 18.06 | 15.34 | 11.72 |
Columns are period end dates · fundamentals updated 26 Oct 2026